real peptides FAQ

Discard the vial immediately without using it. Cloudiness indicates either bacterial contamination or peptide aggregation, both of which render the solution unusable. Mazdutide in proper solution is clear and colourless. Any deviation from that appearance signals degradation or contamination. Aggregated peptides do not dissolve back into solution and cannot bind receptors effectively. Bacterial contamination introduces endotoxins that interfere with experimental outcomes. Never filter or heat a cloudy peptide solution in an attempt to 'fix' it.

Verify the COA includes both HPLC chromatogram and mass spectrometry data. Purity alone doesn't confirm structural integrity. KLOW peptides can show high purity via HPLC while containing fragmented or oxidised omega-3 moieties that don't appear as separate peaks but alter bioactivity. Request MS/MS fragmentation analysis to confirm the omega-3 fatty acid remains conjugated at the correct position. If the supplier cannot provide fragmentation data, the peptide may be structurally compromised despite acceptable purity numbers.

Discard it immediately. Cloudiness or particulate formation indicates peptide aggregation. The amino acid chains have clumped together and lost their native tertiary structure, which is required for receptor binding. Aggregated peptide won't promote wound healing and may trigger localised inflammation if applied to tissue. This typically happens from improper reconstitution technique (injecting solvent directly onto the lyophilised cake), exposure to temperatures above 8°C, or using solvent at the wrong pH.

Discard the vial and do not dose any subjects. Cloudiness or particulate matter after reconstitution indicates one of three failures: the peptide was never pure, it degraded during storage, or the vial contains a substitute compound with different solubility characteristics. Authentic sermorelin acetate has a solubility of approximately 1 mg/mL in water and dissolves completely in bacteriostatic water within 90 seconds. Persistent cloudiness after two minutes of gentle swirling is a hard reject signal. Document the batch number and contact the supplier. If this is a recurring issue across multiple vials, the supplier's cold-chain integrity or synthesis protocols are compromised.

Do not use the peptide for critical research applications. While 96% purity technically falls within some acceptable ranges, authentic cagrilintide batches from reputable synthesis facilities consistently achieve 98–99% purity because the synthesis protocol for this 37-amino-acid sequence is well-established. A 96% reading suggests either incomplete purification, synthesis errors introducing truncated sequences, or intentional dilution with inactive compounds to reduce manufacturing costs. The 2–4% impurity fraction may contain deletion sequences (peptides missing one or more amino acids), oxidized variants, or bacterial endotoxins that interfere with experimental results. Request a replacement batch with documented ≥98% purity or source from a different supplier entirely.

No. Administer the standard afternoon dose (250–500mcg) and resume the normal twice-daily schedule the next day. Doubling a dose doesn't compensate for the missed lipolytic window. It only increases the free fatty acid load without a proportional increase in oxidation capacity, which can impair insulin sensitivity temporarily. AOD-9604 doesn't have the long half-life of compounds like semaglutide where missed doses create therapeutic gaps.

Administer the missed dose as soon as you remember if fewer than 36 hours have passed since the scheduled time. If more than 36 hours have elapsed, skip the missed dose and resume the regular schedule. Do not double-dose. The 20–30 hour half-life means plasma levels remain detectable for 48–72 hours after the last injection, so a single missed dose does not fully reset receptor signaling.

Discard the vial immediately and do not inject. Cloudiness or visible particles indicate protein aggregation. A sign of contamination, incorrect reconstitution technique, or temperature damage during storage or shipping. Properly reconstituted TB-4 should be completely clear with no sediment. Injecting aggregated peptide provides zero therapeutic benefit and introduces contamination risk. If cloudiness appears in a batch from Real Peptides, contact support immediately. Third-party HPLC testing verifies every batch before shipping, and cloudiness post-reconstitution typically indicates user-side storage or technique error rather than product defect.

This is a critical red flag. Either the supplier sent the wrong CoA (administrative error), the vial was mislabeled (quality control failure), or the supplier is providing generic CoAs for all orders regardless of actual batch (fraud). Contact the supplier immediately and request the correct batch-specific CoA. If they can't provide one, or if they claim 'all batches are the same,' assume the peptide is not what the label claims. Batch-specific documentation exists for a reason. Peptide synthesis conditions vary between batches, and purity can fluctuate by 2–5% even within the same facility.

Administer the injection as usual. Do not attempt to withdraw or counteract it. GH pulses above the saturation threshold (200–300 mcg) produce marginal additional release but are not acutely harmful in research models. The excess peptide will be cleared renally within 60–90 minutes without systemic toxicity. The primary consequence is wasted compound, not adverse physiological effects. Skip the next scheduled dose and resume the standard protocol at the following interval to avoid compounding receptor occupancy.

Stop taking NMN or NR after 3 PM and move your dose to morning administration. NAD+ elevation interferes with the natural evening NAD+ decline that signals circadian sleep onset. Research from the Salk Institute found that sustained high NAD+ in the evening delays melatonin secretion by 60–90 minutes and reduces sleep efficiency. The fix: consolidate your full daily dose (250–500mg NMN or 300–600mg NR) into a single morning administration 30–60 minutes before breakfast. If you experience afternoon energy crashes on single-dose protocols, split the dose (two-thirds morning, one-third at lunch) but never later than 2 PM. Sleep architecture matters more than marginal NAD+ gains. Chronic sleep disruption accelerates aging faster than NAD+ supplementation can reverse it.

Yellow discoloration indicates tyrosine oxidation—the peptide is degrading faster than the 28-day stability window for authentic dihexa stored at 2–8°C. This suggests either the lyophilized powder was already partially oxidized before reconstitution or the reconstitution solution introduced contamination. Discard the solution immediately and request stability testing data from your supplier showing degradation rates over 28 days. If the supplier can't provide time-course stability data, their product wasn't tested under proper storage conditions.

Higher doses don't overcome poor timing or environmental interference. If you're taking 10mg at the right time and still awake, the problem isn't insufficient melatonin. It's either delayed sleep phase syndrome (your natural DLMO is later than you think), chronic receptor desensitisation from prior high-dose use, or external factors (light exposure, caffeine, anxiety) that override melatonin's circadian signal. Reduce your dose to 0.5–1mg, move it earlier by 30–60 minutes, and eliminate blue light entirely in the two hours before bed. If sleep latency remains above 30 minutes after two weeks, consult a sleep specialist for DLMO testing. You may need chronotherapy, not more melatonin.

That's a red flag. Legitimate suppliers contract with accredited analytical laboratories (Eurofins, ARL Bio Pharma, Sigma-Aldrich Analytical Services) and include the lab name, address, and accreditation status on every CoA. If the supplier claims 'proprietary testing' or refuses to name the lab, the CoA may be fabricated or based on in-house analysis without independent oversight. In-house testing allows suppliers to manipulate purity claims without accountability. Request a CoA from an accredited third-party lab or source from a different vendor.

Administer the injection at least 20 minutes before eating. Preferably 30 minutes. Injecting within 10 minutes of a meal reduces the functional appetite-stimulation window because ghrelin receptor activation peaks 20–30 minutes post-injection, and if food is already being consumed, insulin elevation blocks the ghrelin signal. The appetite effect doesn't disappear entirely but is measurably blunted. Expect 40–60% reduction in the typical food intake increase compared to properly timed administration.

Discard it and order fresh peptide. Reconstituted AHK-Cu stored at 2–8°C degrades at approximately 15% per week, meaning a vial mixed eight weeks ago retains less than 20% of its original potency. The copper ion catalyzes oxidation of the histidine residue even under refrigeration, and once that bond cleaves, the peptide becomes biologically inert. There's no reliable way to measure remaining potency at home. Attempting to use degraded peptide wastes time and introduces inconsistency into your research protocol. The correct approach: aliquot lyophilized peptide into smaller vials and reconstitute only what you'll use within 10 days.

Monitor serum creatinine, eGFR, and urinary albumin-to-creatinine ratio at baseline, week 4, and study endpoint. The EMBRACE-HFpEF trial tracked these markers across 28 weeks with no change from baseline. Chromaturia is pigment excretion, not tubular injury. SS-31 does not accumulate in renal tissue, and animal toxicology studies at doses 20× human equivalents showed no histopathological changes in kidneys. Persistent concern is a signal for more education about the mechanism, not protocol modification.

Only if one of those peptides is a growth hormone secretagogue. If you're stacking BPC-157 with Ipamorelin, time melatonin relative to Ipamorelin only. BPC-157 doesn't interact. If you're stacking two GH secretagogues together (e.g., CJC-1295 and GHRP-2), dose them simultaneously and take melatonin 60–90 minutes before both.

Cloudiness indicates protein aggregation or particulate contamination. Both are grounds for rejection. Do not inject cloudy peptide solution. Protein aggregates can trigger immune responses and injection-site reactions, and particulate matter (even if not visible to the naked eye) poses embolism risk if injected intravenously by accident. Genuine ipamorelin in proper storage conditions dissolves into a perfectly clear solution. Cloudiness means the peptide was either stored incorrectly (temperature excursions denature the protein), contaminated during lyophilisation, or was never ipamorelin to begin with.

Administer the missed dose as soon as you remember, then resume your regular twice-weekly schedule from that point. Do not double-dose to compensate. TB-4 efficacy is driven by sustained tissue presence, not peak plasma concentration. Missing a single dose delays progress by 3–4 days but does not negate prior administration. If you miss more than two consecutive doses during the critical first two weeks post-injury, restart the protocol from the beginning to ensure adequate coverage during the migration and angiogenesis phase.